75 mg aspirin Gastro - resistant

Aspirin Gastro - resistant 75 mg
ST SPRIN 75

Cardiovascular diseases are a leading cause of death globally, and managing risk factors such as blood clot formation is critical in preventing life-threatening events like heart attacks and strokes. One of the most widely recommended medications for cardiovascular protection is low-dose aspirin.

ST SPRIN 75 is a gastro-resistant tablet containing 75 mg of aspirin, specially formulated for long-term cardiovascular protection. Its enteric-coated design helps minimize gastric irritation, making it suitable for daily preventive therapy in patients at risk of cardiovascular events.

Composition

• Aspirin 75 mg – in a gastro-resistant (enteric-coated) tablet form.

This low-dose, delayed-release formulation ensures that the active ingredient is absorbed in the small intestine rather than the stomach, reducing the risk of gastric discomfort and ulcers often associated with aspirin therapy.

Key Features and Ingredients

Aspirin (Acetylsalicylic Acid) 75 mg

• Belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs).

• Acts primarily as an antiplatelet agent, inhibiting the enzyme cyclooxygenase (COX-1) to prevent the formation of thromboxane A2, a substance that causes platelets to aggregate and form clots.

• Used in low doses to prevent arterial clot formation, particularly in patients at risk of heart attack (myocardial infarction) or ischemic stroke.

• The gastro-resistant coating ensures the tablet bypasses the stomach, reducing the risk of gastric ulcers and bleeding.

Usage Guidelines

Dosage and Administration

• ST SPRIN 75 is typically taken once daily, preferably at the same time each day.

• Swallow the tablet whole with water – do not crush or chew, as this can damage the enteric coating.

• Can be taken with or without food, though taking it after meals may further help reduce gastric discomfort.

Recommended For

• Patients with a history of heart attack or stroke.

• Individuals with coronary artery disease (CAD), peripheral vascular disease (PVD), or atrial fibrillation.

• As a preventive measure in patients with multiple cardiovascular risk factors, such as hypertension, diabetes, high cholesterol, and smoking.

Note: Always use under medical supervision, especially if you are taking other anticoagulants, have a bleeding disorder, or suffer from peptic ulcers.

Clinical Benefits

 1. Cardiovascular Protection

ST SPRIN 75 is primarily used for the secondary prevention of cardiovascular events. By inhibiting platelet aggregation, it reduces the likelihood of arterial clot formation, which can cause heart attacks and strokes.

 2. Gastro-Resistant Formulation

Unlike regular aspirin, ST SPRIN 75 features a gastro-resistant coating that allows the drug to pass through the stomach unaltered and dissolve in the intestine, significantly reducing the risk of gastrointestinal side effects.

 3. Ideal for Long-Term Use

Because of its low dose and gentle formulation, ST SPRIN 75 is suitable for daily, long-term therapy, making it a trusted option in the ongoing management of cardiovascular health.

4. Well-Tolerated and Widely Recommended

Low-dose aspirin has been extensively studied and is widely recommended by cardiologists and general physicians for patients with a high risk of thrombotic events. Its use is backed by clinical guidelines worldwide.

Precautions and Considerations

• Do not use in cases of active bleeding, bleeding disorders, or severe liver or kidney dysfunction.

• Use with caution in asthmatic patients or those with a history of gastrointestinal ulcers.

• Should not be used in children under 16 years unless specifically prescribed, due to the risk of Reye's syndrome.

• Inform your doctor if you are on blood thinners, NSAIDs, or undergoing any surgical procedure.

Conclusion

ST SPRIN 75 is a trusted and effective medication for cardiovascular event prevention, particularly in patients with existing heart disease, stroke history, or risk factors for thrombosis. Its gastro-resistant design, combined with the antiplatelet action of low-dose aspirin, makes it an excellent choice for long-term cardiovascular care. Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options. The company offers a wide range of healthcare products, catering to various medical needs, from rare disease treatments to essential healthcare products. Sterispharma's product range includes solutions for Cardiology, Asthma, Respiratory Issues, Nasal Conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/Antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental Care, and Dermatology. Medicines can be conveniently ordered via Our websites—Sterisonline, Sterisindia, and Sterispharma.

News Referrences: 

• Mumbai Based Steris Healthcare Announces Expansion Plan IPO Launch: msn.com 
• Steris Healthcare Unveils Rs 50 Crore Expansion Plan, Eyes IPO In FY 2026-27 :  bwhealthcareworld.com
• Mumbai-based Steris Healthcare Pvt Ltd plans to launch IPO in FY 2026-27: indianstartupnews.com
• Steris Healthcare Announces Rs 50 Crore Expansion, IPO Planned For FY 2026-27 : News18.com
• Steris Healthcare Pvt Ltd announces ₹50 crore expansion and IPO plans for FY 2026–27:  expresspharma.com

Steris Healtcare: Our Brand Is List On Trusted News Plateform.

Steris Healthcare, a pharmaceutical company headquartered in Mumbai, has announced a strategic expansion plan worth ₹50 crore. The initiative includes setting up a new manufacturing facility in South India, doubling its current production capacity, and preparing for an Initial Public Offering (IPO) scheduled for the financial year 2026–27.

Having surpassed ₹100 crore in annual sales, Steris Healthcare aims to strengthen its nationwide footprint by expanding into key southern markets such as Kerala, Tamil Nadu, Telangana, and Karnataka. The upcoming manufacturing unit is expected to play a crucial role in enhancing the company's production capabilities and meeting the rising demand from both domestic and international markets.

For further information 

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW